Company news
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) news
Edgewise Therapeutics, Inc. news releases on 6ix. Latest, Apr 23, 2024: Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations…
Press releases — page 2
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
April 22, 2024
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
April 14, 2024
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
March 27, 2024
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
March 26, 2024
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
March 4, 2024
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
February 27, 2024
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
February 21, 2024
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
February 12, 2024
Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock
January 18, 2024
Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
January 8, 2024
Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
December 18, 2023
Edgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy Community
December 17, 2023
Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA
November 29, 2023
Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 8, 2023
Edgewise Therapeutics to Present at Upcoming Investor Conferences
November 7, 2023
Edgewise to Present Data on EDG-7500 at the American Heart Association’s Scientific Sessions 2023
October 31, 2023
Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne)
October 25, 2023
Edgewise Therapeutics to Present on EDG-5506 for Becker Muscular Dystrophy at the 28th International Annual Congress of the World Muscle Society
September 26, 2023
Edgewise Therapeutics Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker)
September 25, 2023
Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction
September 13, 2023
Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 9, 2023
Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
June 25, 2023
Edgewise Therapeutics to Present at the Goldman Sachs Global Healthcare Conference
June 5, 2023
Edgewise Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 10, 2023
Edgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models of Duchenne Muscular Dystrophy (DMD)
March 29, 2023
Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023
March 20, 2023
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference
March 13, 2023
Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors
March 5, 2023
Edgewise Therapeutics to Present at the Cowen 43rd Annual Health Care Conference on March 8, 2023
February 28, 2023
Edgewise Therapeutics Announces Upcoming Presentation at the American College of Cardiology's 72nd Annual Scientific Session Together with World Congress of Cardiology
February 27, 2023
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
February 22, 2023
Edgewise Therapeutics to Present at the SVB Securities Global Biopharma Conference on February 14, 2023
February 6, 2023
Edgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
January 3, 2023
Edgewise Therapeutics to Showcase Novel Cardiac Program at Virtual Investor Event on Tuesday, January 3, 2023
December 20, 2022
Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer
December 19, 2022
Edgewise Therapeutics Reports Third Quarter 2022 Financial Results
November 2, 2022
Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
October 26, 2022
Edgewise Therapeutics Announces Positive 6-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
October 12, 2022
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 27th International Hybrid Annual Congress of the World Muscle Society
October 5, 2022
Edgewise Therapeutics Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 15, 2022
Edgewise Therapeutics Announces Proposed Offering of Common Stock
September 12, 2022
Edgewise Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
September 12, 2022
Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
September 10, 2022
Edgewise Therapeutics Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
September 6, 2022
Edgewise Therapeutics Reports Second Quarter 2022 Financial Results
August 3, 2022
Edgewise Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on August 9
August 2, 2022
Edgewise Therapeutics Now Enrolling CANYON Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)
July 11, 2022
Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
June 19, 2022
New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeletal Muscle Conference
June 15, 2022
Edgewise Therapeutics Reports First Quarter 2022 Financial Results
May 10, 2022